Effectiveness of XBB.1.5 vaccines against symptomatic SARS-CoV-2 infection in older adults during the JN.1 lineage-predominant period, European VEBIS primary care multicentre study, 20 November 2023--1 March 2024

Lore Merdrignac; Charlotte Laniece Delaunay; Nuno Verdasca; Lorena Vega Piris; Joan O'Donnell; Noémie Sève; Camino Trobajo-Sanmartín; Silke Buda; Mariette Hooiveld; Ana Paula Rodrigues; Gergő Túri; Neus Latorre-Margalef; Ivan Mlinarić; Mihaela Lazar; Marine Maurel; Daniel Castrillejo; Charlene Bennett; Marie-Anne Rameix-Welti; Iván Martínez-Baz; Ralf Dürrwald; Adam Meijer; Aryse Melo; Beatrix Oroszi; Tove Samuelsson Hagey; Sanja Kurečić Filipović; Frederika Dijkstra; Verónica  Gómez; Sabrina Bacci; Marlena Kaczmarek; Esther Kissling

doi:10.22541/au.172115251.10805606/v1

loading page

Effectiveness of XBB.1.5 vaccines against symptomatic SARS-CoV-2 infection in older adults during the JN.1 lineage-predominant period, European VEBIS primary care multicentre study, 20 November 2023--1 March 2024

Lore Merdrignac,
Charlotte Laniece Delaunay,
Nuno Verdasca,
Lorena Vega Piris,
Joan O'Donnell,
Noémie Sève,
Camino Trobajo-Sanmartín,
Silke Buda,
Mariette Hooiveld,
Ana Paula Rodrigues,
Gergő Túri,
Neus Latorre-Margalef,
Ivan Mlinarić,
Mihaela Lazar,
Marine Maurel,
Daniel Castrillejo,
Charlene Bennett,
Marie-Anne Rameix-Welti,
Iván Martínez-Baz,
Ralf Dürrwald,
Adam Meijer,
Aryse Melo,
Beatrix Oroszi,
Tove Samuelsson Hagey,
Sanja Kurečić Filipović,
Frederika Dijkstra,
Verónica Gómez,
Sabrina Bacci,
Marlena Kaczmarek,
Esther Kissling

Abstract

not-yet-known not-yet-known not-yet-known unknown We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥65 years during the 2023/24 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: -11–48) and 5% (95% CI: -92–56) among those with symptom onset 1–5 , 6–11, and ≥12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.

Submitted to Influenza and other respiratory viruses

Show details

Hide details

Submission Checks Completed

Assigned to Editor

Reviewer(s) Assigned

Abstract

Peer review status:UNDER REVIEW